Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Taiwan University Hospital
With
TTY Biopharm
Age
20–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histologically or cytologically proven, newly diagnosed pancreatic adenocarcinoma or adenosquamous carcinoma
no previous radiotherapy, chemotherapy, targeted therapy, curative surgery, or immunotherapy used for pancreatic cancer
presence of at least one measurable lesion, which must meet the criteria of being ≥ 20 mm in at least one dimension by conventional CT/MRI or ≥ 10 mm by spiral CT scan
age between 20 and 79 years at registration
ECOG PS of 0 or 1
adequate major organ functions
ability to take the oral study medication (TS-1)
no clinically significant abnormal ECG findings within 28 days (4 weeks) prior to registration
voluntarily signed the written informed consent form
You may not be if
pulmonary fibrosis or interstitial pneumonitis diagnosed within 28 days prior to registration
presence of diarrhea ≥ CTCAE v.4.03 grade 2
concomitant active infection or significant co-morbid medical conditions
moderate or severe ascites or pleural effusion that requires drainage
central nervous system metastasis
prior or concurrent malignancies within the last 3 years
concomitant treatment with flucytosine, phenytoin or warfarin
pregnant women or nursing mothers, or positive pregnancy test
severe mental disorder
judged ineligible by physician for participation in the study due to safety concern
Clareo Health | Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
